I01 Multimodal MRI assessment: a biomarker of presymptomatic Huntington's disease

Squitieri, F; Sanchez-Castaneda, C; Cherubini, A; De Gregorio, F; Sabatini, U
September 2010
Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA36
Academic Journal
Background Neuroimaging studies showed impairment of the basal ganglia and thalamus in preclinical stages of Huntington's disease (HD) characterised by progressive volume loss, microstructural impairment and microglial activation. Therefore, biomarkers sensitive to all of these changes are needed. Aims We assessed the multimodal MRI as biomarker of the disease vulnerability and progression. Methods 3D T1 weighted image MRI acquisition was performed on a 3T Siemens scanner. We evaluated the macrostructure, microstructure and iron content of five vulnerable subcortical structures (high risk: caudate, putamen and pallidus; and low risk: thalamus and accumbens) in comparison with medial temporal lobe structures (hippocampus and amygdala) relatively preserved in early stages of the disease. 17 presymptomatic, 14 symptomatic (stages I–II) and 31 age and gender matched control subjects were scanned using the same protocol. Results Pre-HD subjects had a selective decrease of volume and microstructural changes in high risk structures (caudate, putamen and pallidus) and increased iron accumulation in all three nuclei (but only statistically significant in the globus pallidus). HD patients had lower volume than pre-HD in all high risk nuclei, higher microstructural impairment in the striatum but not significant differences in iron content. The lesion extended to low risk subcortical nuclei (thalamus and accumbens). Furthermore, volume and microstructure correlated with the clinical measures of progression of the disease. Conclusions This study provides proof of in vivo selective striatal degeneration in presymptomatic stages of the disease. Different parameters of MRI acquisition provide complementary information that give clues to the understanding of the pathophysiology underlying HD and its progression.


Related Articles

  • Presymptomatic testing for Huntington's disease in the United Kingdom. Tyler, Audrey; Ball, David; Cranfurd, David // BMJ: British Medical Journal (International Edition);6/20/92, Vol. 304 Issue 6842, p1593 

    Evaluates the presymptomatic testing for inherited disorder Huntington's disease in Great Britain. Reduction of risk in carrying Huntington disease gene; Median age for presymptomatic testing of the disease; Decrease in the demand for presymptomatic testing.

  • Presymptomatic testing for Huntington's disease. Wexler, Nancy // National Forum;Spring93, Vol. 73 Issue 2, p22 

    Discusses issues associated with presymptomatic and prenatal testing for Huntington's disease. Guidelines for testing; Attitudinal surveys prior to test availability; Outcomes from presymptomatic-linkage testing for the allele of Huntington's disease; Family as a testing partner.

  • Genetic discrimination: Huntington's disease and the Americans with Disabilities Act. Gin, Brian R. // Columbia Law Review;Jun97, Vol. 97 Issue 5, p1406 

    Discusses generally the problems of genetic discrimination, and addresses specifically the issue of whether presymptomatic persons who test positive for Huntington's disease are with a `disability' within the meaning of the Americans with Disability Act (ADA). Use of analogy between...

  • Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease. Wolf, Robert C; Gr�n, Georg; Sambataro, Fabio; Vasic, Nenad; Wolf, Nadine D; Thomann, Philipp A; Saft, Carsten; Landwehrmeyer, G Bernhard; Orth, Michael // Journal of Cerebral Blood Flow & Metabolism;Sep2011, Vol. 31 Issue 9, p1908 

    Magnetic resonance imaging (MRI) of the brain could be a powerful tool for discovering early biomarkers in clinically presymptomatic carriers of the Huntington's disease gene mutation (preHD). The aim of this study was to investigate the sensitivity of resting-state perfusion MRI in preHD and to...

  • T2-weighted MRI detects presymptomatic pathology in the SOD1 mouse model of ALS. Evans, Matthew C; Serres, Sébastien; Khrapitchev, Alexandre A; Stolp, Helen B; Anthony, Daniel C; Talbot, Kevin; Turner, Martin R; Sibson, Nicola R // Journal of Cerebral Blood Flow & Metabolism;May2014, Vol. 34 Issue 5, p785 

    Neuroinflammation has been identified as a potential therapeutic target in amyotrophic lateral sclerosis (ALS), but relevant biomarkers are needed. The superoxide dismutase (SOD1)G93A transgenic mouse model of ALS offers a unique opportunity to study and potentially manipulate presymptomatic...

  • Functional and Structural MRI Biomarkers to Detect Pre-Clinical Neurodegeneration. Abdulkadir, Ahmed; Ronneberger, Olaf; Wolf, Robert Christian; Pfleiderer, Bettina; Saft, Carsten; Kloppel, Stefan // Current Alzheimer Research;Feb2013, Vol. 10 Issue 2, p125 

    The availability of an accurate genetic test to identify Huntington's Disease (HD) in the pre-symptomatic stage makes HD an important model to develop biomarkers for other neurodegenerative diseases, such as pre-clinical Alzheimer's Disease. We reasoned that functional changes, measured by...

  • The impact of presymptomatic testing for Huntington's disease on marital relationships and partners. Bruce, Anita; Simpson, S. A.; Semper, J. // Journal of Medical Genetics;Sep2005, Vol. 42, pS122 

    Presents an abstract of the article "The Impact of Presymptomatic Testing for Huntington's Disease on Marital Relationships and Partners," by Anita Bruce, S. A. Simpson and J. Semper.

  • Finding Order in Alzheimer's Biomarkers. Relkin, Norman // Neurology Alert;Oct2011, Vol. 30 Issue 2, p11 

    Measurement of biomarkers, including Aß42 and tau protein in the CSF along with volumetric measurements of the hippocampus, may help in the diagnosis of early or presymptomatic Alzheimer's disease.

  • Biomarkers and the Diagnosis of Alzheimer's Disease. Lin, Michael // Internal Medicine Alert;11/15/2012, Vol. 34 Issue 21, p164 

    Biomarkers in the cerebrospinal fluid open the possibility of diagnosing early or even presymptomatic cases of Alzheimer's disease, thereby expanding the potential window for therapy.


Read the Article


Sign out of this library

Other Topics